Business Development
Myrexis, Inc. is committed to bringing first-in-class / best-in-class therapeutics to cancer patients. To do this, we intend to develop strategic alliances with partners that can provide the expertise and resources to fully realize the potential of our novel development compounds while minimizing the risk of failure inherent to drug discovery. These collaborations will provide near-term revenue to advance our earlier stage assets into product opportunities while providing a long-term financial upside through milestone payments, royalty revenue and commercialization in the US.
Our Current Partnering Opportunities include:
- Azixa™ (MPC-6827) for brain cancer
- MPC-3100 for cancer
- HIV portfolio
- MPC-9528 for cancer
- MPI-0485520 for cancer and inflammation
If you are interested in learning more about our development candidates or collaborating with Myrexis, Inc., please contact our Business Development group:
Joshua T. Jones, Ph.D.
Manager, Business Development
(p) 801-214-7876
business.development@myrexis.com

